An interventional study of mirtazapine and mirtazapine in Depression and Anxiety, sponsored by Universidad Nacional de Rosario. Completed at 1 site in Argentina. Open to participants aged 65 Years to 87 Years. Per ClinicalTrials.gov, last updated 2009-08-18.
Sponsored by Universidad Nacional de Rosario · Not applicable, Interventional, and Prevention
The purpose of this study is to evaluate if the use of antidepressant medication in depressed patients with implantable cardioverter defibrillator reduces the number of ICD's shocks as it improves depressive affect.
episodes of arrhythmia remain present even after icd implantation, this is specially true in depressed patients. it is hypothesized that improving mood state by means of an antidepressant drug . namely mirtazapine. could be responsible of alleviating the number of appropriate shocks delivered by the cardioverter. this could be due to a direct effect of the drug itself or an indirect effect of improving anxious and depressive affect. the mood and anxiety state are measured with the HADS scale
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 40 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →Universidad Nacional de Rosario is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: mirtazapine
Drug: mirtazapine
mirtazapine 15 mg daily tablets
Also known as: mirtazapine 1500 mtz
15 mg daily
Also known as: remeron 1569 rem
number of implantable cardioverter defibrillator shocks
Time frame: one year
improvement of depression
Time frame: one year
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Nacional de Rosario